Korean J Med > Volume 77(2); 2009 > Article
The Korean Journal of Medicine 2009;77(2):152-156.
Current status of drug-resistant tuberculosis and its treatment
Jae-Joon Yim
내성 결핵균의 실태 및 치료
임 재 준
Abstract
Drug-resistant tuberculosis (TB), especially multidrug-resistant (MDR)-TB and extensively drug resistant (XDR)-TB, poses a serious threat to global health because it requires treatment for a long duration and frequent hospitalization, and results in a considerable number of mortalities. In South Korea, MDR is observed in 2.7% of newly diagnosed TB cases and in 14% of re-treatment cases. In addition, 5~20% of MDR-TB could be categorized as XDR-TB. Treatment regimen for MDR or XDR-TB should include 4~5 drugs susceptible to isolated tuberculous bacilli and should be maintained at least 18 months after culture conversion. Pertinent combination of anti-TB drugs and solid compliance are the basis of successful treatment for MDR and XDR-TB patients. (Korean J Med 77:152-156, 2009)
Key Words: Tuberculosis; Drug resistance; Treatment


TOOLS
METRICS Graph View
  • 1,258 View
  • 11 Download

Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6791    Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr                

Copyright © 2024 by The Korean Association of Internal Medicine.

Developed in M2PI

Close layer
prev next